Not sure you saw this...but some serious house cleaning took place last week.

"The Purge" occurred on 25Aug22.

https://nypost.com/2022/08/25/pharma-bro-martin-shkreli-booted-from-his-company-by-activist-revolt/

House cleaning in progress at many places Marty has touched over the years. Likely going to take a while to cleanse the SEC's palette of Marty's former presence.

After careful reconsideration, I am amending my original terming of Dr. Kelly's nickname. She should be referred to as:

Deborah "DIAMOND HANDS" Kelly, MD, FACP

And what I find interesting is that Scott Kelly's very first Form 3 with CytoDyn from when he became a director in April 2017 has Deborah Kelly coming on the radar by already owning 691,208 shares.

https://www.sec.gov/Archives/edgar/data/0001703394/000089924317010063/xslF345X03/doc3.xml

So....Deborah Kelly has been HODLING for over 5 years now and has been accumulating...

What kind of doctor is she.....let's see...

Board certified in Internal Medicine in 1998......
An Adjunct Associate Professor of Medicine at Emory School of Medicine.....
A Fellow of American College of Physicians.....
Active in the American College of Physicians-American Society of Internal Medicine, the American Medical Association, and the Royal College of Physicians....
Attended the Lovett School in Atlanta....
Graduated Cum Laude from Wake Forest University....
Attended Medical School at the Medical College of Georgia....
Completed internship and residency at Emory University School of Medicine....

That sounds like a very qualified medical doctor and someone who understands quite a bit about of why leronlimab can be beneficial in medicine...

Deborah "HODLING" Kelly, MD, FACP

Nothing conflicting about these Form 4s with the exception of basic understanding of what they mean. Everyone should probably read a little closer. Those "D" and "A" entries can be confusing as can be footnotes. These are NOT conflicting, they stand as separate Form 4 filings.

Disposed of "Old CytoDyn" shares (merged into Point NewCo Inc and renamed "New CytoDyn"). Zeroed out ALL shares in old company.

Acquired "New CytoDyn" shares in exactly the same quantity. Notice the Table I, Column 5 quantities? Matches Column 4 "A" acquired amounts - exactly.

This completely makes it understandable why Deborah Kelly's Form 144 was turned into the apocalypse ....notably by Adam Feuerstein...that reminds me....some hungarian goulash for dinner sounds great.

So, some astute post here pointed out that today's trading was so evenly balanced that it was "wash trading" that created artificial activity in the marketplace.

So, if there is an even volume on the buying and selling side that scenario might be remotely plausible.

But, can someone explain how short volume that constitutes over 50% of the day's volume contributes to "wash trading" ?



Sounds like more made up malarkey.

Hmmmm.... "everyone" says the shorts know something... But I know this much... even took an online lesson to get better smartest faster. They say 20% to 30% is a typical borrow fee for a high demand stock... But for CYDY that's so last week... We're now 5X that rate.... 130.63% per annum to be precise... And that changes daily without notice based on a 360 day year. That means right now it's costing to borrow 5X what it did last week.... For *ALL* shorts regardless when they borrowed the shares....sooo... you have to also remember that to borrow penny stocks...the $2.50 Rule....Most brokers have this rule that applies to shorting stocks under $2.50. You’ll need $2.50 of capital for each share, even if the stock is priced much lower.

So, I hope they all know this.....

..... But other than that...I just know that all I have to do is make sure my shares aren't in a margin account and no stop losses.

Eazy Peazy

Oh... And they're "connected".... Connected to what?? Connected like this?

Well, can't blame it on low volume spiking or slapping the ask. This is sustained buying and not a lot of selling it looks like. Lots of longs going with the program and holding on for the ride. Should be interesting when the good news comes out....

...oops...did I just say that out loud?


Going to sit back, pop open a cold one, review my trades, and turn on some mellow music....hmmmm....how about about Eric Clapton's remake of Danny Flower's "Tulsa Time"....

I heard an unsubstantiated rumor that NP had taken all those warrant conversion/sale profits from Apr 2020 and is buying his way back into the company...is it 5% or 10% that he'd have to file a 13D ?

Inquiring minds want to know....

Where is it documented that "Khazampour and Pourhassan instigated and mulholland oversaw" a "fraud scheme"?

Blowing more smoke into an already smokey situation just yields even more smoke.

Not picking up what you're putting down.....I'll let somebody else step in that.


....TIN FOIL !!! GONNA NEED MORE TIN FOIL !!!!

From sniffing around....my thought is this is probably related to the FIFE notes and that Tony Migs waited until the last minute thinking 5 Monster Ultra Fiesta Mangos could get him through Sunday night to have it delivered by this morning. Sadly it's not that simple of a process in such a short time. Plus Tony Migs has a new accounting firm looking over his shoulder....and they don't want to run afoul of any regulatory agency either......So, more time is needed to correctly "'splain tings".

https://www.eisneramper.com/convertible-debt-accounting-te-blog-0921/

I'm smelling the odors of "debt extinguishment and modifications".

Either way, I bet they file a NT-10K before business hours tomorrow or on Aug 16.

The vibe I'm getting from CytoDyn...which is really difficult to read right now...is that their HIV push is really faltering. I have a suspicion any talk of HIV is going to slowly be pushed under the covers. The BLA filing looks more and more distant....if at all.

Hopefully Martin's prior influence and memory is waning and that's a good thing to keep this a clean shell company.

Ran across the latest filing in the LIFEMD, INC et al v. LAMARCO et al case. Seems that Lamarco's lawyers got a smackdown on their "Motion to Reconsider its Motion to Dismiss" - the court responded with a "DENIED" in capital letters.

https://www.pacermonitor.com/public/case/41996546/LIFEMD,_INC_et_al_v_LAMARCO_et_al
One statement that stood out of the filing was:

Judges typically don't appreciate being told what to do, how to do it, and especially questioned on what they've already ruled on.

".....bailiff, whack his pee-pee"

Apparently no one has posted all the "A lot is known" links here....because sharing is caring.

No SEC/DOJ FOIA requests have been submitted in quite a long time. So, unless the company or the SEC made some press announcement, there is still yet near ZERO details known.

So...in the absence of all those links...I'm going to just blame Canada.

Absolutely nothing is known about these investigations other than that they exist.

So, my guess is as valid as an other.....

Wouldn't it be something if the 10K details were leaking out and it has the phrase "received SEC Termination Notice" buried in there?

s3.....your move.

More than a sign of strength....think of it as a....message.

Let's see....15 pages in front for the Title, dedication, forward, table of contents, copywrite, personal notes, etc....

...then 8 pages in the back for the closing thoughts, index, etc..

That leaves 23 pages for content....

Let's say 6 chapters...each has it's own title page...that leaves 17 pages of content....

...anyone want to throw in 6 pages of pictures....or ready to "color by numbers" pictures?

A page 5.75" x 8.75 contains about 250 words (double spaced or large "easy to read type")....which means...

...about 11 pages of content ....each page has two sides....let's be generous and say they're filled up....

...comes out to 5,500 words.....

Compare that to these literary greats:
22,416 words – The Mouse and the Motorcycle – Beverly Cleary
30,644 words – Charlie and the Chocolate Factory – Roald Dahl

...or...you can look at the $26.34 cost, divide that by 46 pages.....that comes out to $0.5726 per page....each of those pages were worth more than a share of CYDY on Wednesday afternoon this week.....

Have a great weekend to all.

Wonderful....thanks for the updated info. I sit corrected.

Consider the timeline of events before attempting correlation or causation.

Kelly publishes book March 2015.
https://www.amazon.com/What-Ive-Learned-You-Patients/dp/0991274326

Kelly appointed Chief Medical Officer and Head of Business Development in April 2020.
https://www.globenewswire.com/news-release/2020/04/13/2014953/0/en/CytoDyn-Appoints-Scott-A-Kelly-M-D-as-Chief-Medical-Officer-and-Head-of-Business-Development.html

Moneycrew....let me try to do this helpfully.....

This property on July 11, 2016 was bought by Arvin Arman (hint...his middle name is "Cyrus") and his beautiful wife Melissa. Then at the later stages of closing and prior to the deed being recorded, there was an additional name added to the deed - "Arman Cyrus Trust". Then a few years went by....Then on May 6, 2022 both Arvin Arman and Melissa sold their interest in the home to the "Arman Cyrus Trust" for a sum of $670,000. This means that Arvin Arman and Melissa no longer hold any separate share of the ownership of that property - the "Arman Cyrus Trust" is full owner and controller of the property.

Now, who the members of the "Arman Cyrus Trust" are is a private matter. But lets just make it known that any child or children of Arvin and Melissa are currently minors and can't make legal decisions on their own....even if they do have a large box of crayola crayons to sign documents with....a box so large that some here would covet it for their own.....

Was it you who was looking for the screenshot from this publication?



And if there are any requests for further excerpts from this document....go get a library card.

Not sure about expecting headlines or hype. Have you seen ANY PRs from CYDY?

None about their presentations at international conferences. None about their PIPE. Not one about their new President even. Want to know what's going on.... Gotta check their 8-K fillings.

It appears to be the new paradigm post Nader.

No disagreement with 99% said...but CytoDyn did just finish another raise through Paulson for about $19MM. That should keep the lights on for a while longer.

Also, I think "The Bobs" will be paying SK a visit soon....

What's so great about standards....is that there are so many to choose from....

Taking a look at this:
https://www.healthit.gov/isa/submission-clinical-research-data-fda-support-product-marketing-applications

You see that several are in "Implementation Maturity" of "Production".... but "Adoption Level" is very low. Not sure of the date of information though. Good site to peruse if data is your thing.

Also:

https://www.fda.gov/industry/fda-data-standards-advisory-board/study-data-standards-resources

https://emcifund.com/our-team/

You see that he has experience with hedge funds? Wonder how he's going to apply that knowledge to maneuvering toward bolstering stock value and uplisting.

BioVega Capital
https://www.linkedin.com/company/biovega-capital-llc/about/

Speaking of short selling...which seems to be continuing en masse up to the CC...I was reading this paper over that I found on the SEC website:

https://www.sec.gov/comments/s7-08-08/s70808-318.pdf

Very informative. And what is this...thing...they mention...."n-a-k-e-d s-h-o-r-t-i-n-g"...."naked" only shows up 121 times in the document. Must be a real thing.

Anniversaries all around today !!!

30Jun is a day that many can't forget...nor should they.

I've lost track of the number of shares sold in 100 share blocks...but it's probably up to 20K or so in the last hour. Add those to the 52+MM short shares already out...

Also watching the trades. A significant batch of 100 block shares being sold into the uptick. Looks like a crapload of shares being sold short right before the CC.

Prob not a bad decision based on previous CCs. But, then again who knows what's going to be announced...or not...during the CC.

Did anyone notice that the FTDs for the first half of June 2022 are noticeably lower than any reporting periods in the last couple of years?



Seems that Fife has stopped dumping shares into the market and that few, if any, warrant holders are "dumping" as soon as they receive them. Both good signs.

FTDs for the last year:

Soooooooo........everyone have their Q's submitted and expect to get A's back?

GLTA Long Investors

So, stock manipulation was the first thing to come to mind? Must say a lot about that... Because there was nothing mentioned in my post about that.

Meh. The short interest % to float is 7.91% now.

It's like a flaming chainsaw spinning in the air.....which end is going to get grabbed and by who.

New bi-monthly data released by FINTEL:
https://fintel.io/ss/us/cydy


Dang short interest is at an all time high. Fail To Delivers (FTD) not updated just yet, but that should be interesting also.

And there won't be anything found about Arian Colachis leaving CytoDyn employment either. Some things just don't make the front page news every day.

https://www.sec.gov/Archives/edgar/data/0001175680/000119312520220598/d923315dex1063.htm

It ain't gonna be found in there....but keep looking.

Something that everyone has failed to remember....I was waiting to see if they were going to....I've waited long enough....but....did anyone subtract the clawback of awards that were documented here?

These shares would be given back into the pool of available "Amended and Restated 2012 Equity Incentive Plan" pool of shares available for award.
Found in Note 10 (Page 123) of the FY21 10-K.
https://www.cytodyn.com/investors/sec-filings/annual-reports?form_type=10-K&year=

As for mentioning a sub-clause of a plan in an SEC filing.....think of it this way...if all sub-clauses of every plan mentioned in a 10-K were included it would make reading these documents even more arduous. But, for sake of knowing that CytoDyn recognized and filed a declaration of their "Amended and Restated 2012 Equity Incentive Plan", look no further than their FY21 10-K report - Note 7 (Page 113) which states:

https://www.cytodyn.com/investors/sec-filings/annual-reports#document-18042-0001558370-21-009730

Not sure it is understood that CytoDyn's "Amended and Restated 2012 Equity Incentive Plan" is not a contract between parties but is an internal "benefit" plan that "provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to the Company’s employees (and the employees of any subsidiary), non-employee directors, and outside consultants or advisers." Pretty sure it's not covered under the consumer contractual law cited. If anyone feels that it falls under a "consumer contract" then I encourage to file a case with the Delaware Chancellery (https://courts.delaware.gov/chancery/) - I direct attention to the section "Attorneys and Litigants" for detailed information on directions to get a suit filed.

If there's any question of the "Amended and Restated 2012 Equity Incentive Plan" being approved or not, please refer to the 8-K announcing the passing of it by a narrow margin in favor.
https://www.cytodyn.com/investors/sec-filings/all-sec-filings/content/0001193125-20-261200/d935957d8k.htm?TB_iframe=true&height=auto&width=auto&preload=false

It's spelled out pretty clear in this 8-K (Oct 1, 2020) that everyone should have read.

https://www.sec.gov/Archives/edgar/data/1175680/000119312520261200/d935957d8k.htm

Oh...forgot to ask if the "Evergreen Increase" was added to those numbers. It's spelled out right in the SEC Filing for the Sep 30, 2020 " PROXY STATEMENT - 2020 ANNUAL MEETING OF STOCKHOLDERS". This agenda item was voted on and passed so it's clearly in effect...in addition to that 25,000,000 extra share increase.

https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-20-237251.html?hash=9ba8ef26185f5e0f973f3b9a92a0f5bed5bbcdb1e745a2dc00265d73e847047a&dest=D32983DDEF14A_HTM#D32983DDEF14A_HTM

By my calculations for the CYDY Fiscal Year 2021 and 2022 the values would be (based on open shares on May 31 of each year):

FY 2021 Evergreen: 6,256,800 (625,680,000 Shares Out * 0.01)
FY 2022 Evergreen: 7,189,400 (718,940,000 Shares Out * 0.01)
Total so far: 13,446,200 shares

Yes, "maff" is adding all the numbers up in front of ones eyes. But, ahhh..."analytics" is knowing what numbers are supposed to be added.